Intrinsic value of Qiagen - QGEN

Previous Close

$31.52

  Intrinsic Value

$16.41

stock screener

  Rating & Target

sell

-48%

  Value-price divergence*

+79%

Previous close

$31.52

 
Intrinsic value

$16.41

 
Up/down potential

-48%

 
Rating

sell

 
Value-price divergence*

+79%

*Intrinsic value change (in %) minus stock price change (in %) in the past 12 months.

We calculate the intrinsic value of QGEN stock by summing up the current values of future distributable cash flows generated by the company and dividing the sum by the number of outstanding shares. As such, the intrinsic value calculation depends entirely on projections. The more accurate your projections of the company's performance are - the more reliable is the intrinsic value calculation result. Please make sure to check the stock valuation input data below and adjust it if necessary. The quality of the output (intrinsic valuation result) is only as good as the quality of the input. See also DISCLAIMERS.

STOCK VALUATION INPUT DATA

Revenue (in 2016), $M
Initial revenue growth rate, %
Terminal revenue growth rate, %
Revenue decline factor
Initial discount rate, %
Discount rate multiplier
Variable cost ratio, %
Fixed operating expenses, $M
Interest rate on debt, %
Effective corporate tax rate, %
Production assets / Revenue, %
Life of production assets, yrs
Working capital / Revenue, %
Revenue / Adjusted assets
Adjusted equity ratio
Cash flow adjustment, % of Revenue
Book value of equity, $M
Shares outstanding, mln
Market capitalization, $bln 7.2

 

FINANCIAL STATEMENTS FORECAST and PRESENT VALUE CALCULATION

Fiscal year
2016(a)
   2017
   2018
   2019
   2020
   2021
   2022
   2023
   2024
   2025
   2026
   2027
   2028
   2029
   2030
   2031
   2032
   2033
   2034
   2035
   2036
   2037
   2038
   2039
   2040
   2041
   2042
   2043
   2044
   2045
   2046

INCOME STATEMENT

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Revenue growth rate, %
  4.45
  3.40
  3.56
  3.70
  3.83
  3.95
  4.06
  4.15
  4.23
  4.31
  4.38
  4.44
  4.50
  4.55
  4.59
  4.63
  4.67
  4.70
  4.73
  4.76
  4.78
  4.81
  4.82
  4.84
  4.86
  4.87
  4.89
  4.90
  4.91
  4.92
  4.92
Revenue, $m
  1,338
  1,383
  1,433
  1,486
  1,543
  1,604
  1,669
  1,738
  1,812
  1,890
  1,972
  2,060
  2,153
  2,251
  2,354
  2,463
  2,578
  2,699
  2,827
  2,962
  3,103
  3,253
  3,410
  3,575
  3,748
  3,931
  4,123
  4,325
  4,537
  4,760
  4,995
Variable operating expenses, $m
 
  1,182
  1,217
  1,255
  1,296
  1,339
  1,386
  1,435
  1,488
  1,544
  1,603
  1,473
  1,539
  1,609
  1,683
  1,761
  1,844
  1,930
  2,022
  2,118
  2,219
  2,326
  2,438
  2,556
  2,680
  2,811
  2,948
  3,092
  3,244
  3,404
  3,571
Fixed operating expenses, $m
 
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Total operating expenses, $m
  1,239
  1,182
  1,217
  1,255
  1,296
  1,339
  1,386
  1,435
  1,488
  1,544
  1,603
  1,473
  1,539
  1,609
  1,683
  1,761
  1,844
  1,930
  2,022
  2,118
  2,219
  2,326
  2,438
  2,556
  2,680
  2,811
  2,948
  3,092
  3,244
  3,404
  3,571
Operating income, $m
  99
  202
  216
  231
  247
  264
  283
  303
  324
  346
  369
  587
  613
  641
  671
  702
  735
  769
  806
  844
  884
  927
  972
  1,019
  1,068
  1,120
  1,175
  1,232
  1,293
  1,356
  1,423
EBITDA, $m
  312
  472
  489
  507
  526
  547
  569
  593
  618
  645
  673
  703
  734
  768
  803
  840
  879
  921
  964
  1,010
  1,059
  1,109
  1,163
  1,219
  1,279
  1,341
  1,406
  1,475
  1,548
  1,624
  1,704
Interest expense (income), $m
  18
  37
  39
  42
  44
  46
  49
  52
  55
  58
  62
  66
  70
  74
  78
  83
  87
  93
  98
  104
  110
  116
  123
  130
  137
  145
  153
  161
  170
  180
  190
Earnings before tax, $m
  57
  164
  176
  189
  203
  218
  234
  251
  268
  287
  308
  521
  544
  568
  593
  619
  647
  677
  708
  740
  775
  811
  849
  889
  931
  975
  1,022
  1,071
  1,123
  1,177
  1,234
Tax expense, $m
  -23
  44
  48
  51
  55
  59
  63
  68
  72
  78
  83
  141
  147
  153
  160
  167
  175
  183
  191
  200
  209
  219
  229
  240
  251
  263
  276
  289
  303
  318
  333
Net income, $m
  80
  120
  129
  138
  148
  159
  171
  183
  196
  210
  224
  381
  397
  414
  433
  452
  472
  494
  517
  540
  566
  592
  620
  649
  680
  712
  746
  782
  819
  859
  900

BALANCE SHEET

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cash and short-term investments, $m
  532
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Total assets, $m
  4,308
  3,908
  4,047
  4,197
  4,358
  4,530
  4,714
  4,910
  5,118
  5,338
  5,572
  5,819
  6,081
  6,358
  6,650
  6,958
  7,283
  7,626
  7,986
  8,367
  8,767
  9,188
  9,631
  10,098
  10,588
  11,104
  11,647
  12,217
  12,817
  13,447
  14,109
Adjusted assets (=assets-cash), $m
  3,776
  3,908
  4,047
  4,197
  4,358
  4,530
  4,714
  4,910
  5,118
  5,338
  5,572
  5,819
  6,081
  6,358
  6,650
  6,958
  7,283
  7,626
  7,986
  8,367
  8,767
  9,188
  9,631
  10,098
  10,588
  11,104
  11,647
  12,217
  12,817
  13,447
  14,109
Revenue / Adjusted assets
  0.354
  0.354
  0.354
  0.354
  0.354
  0.354
  0.354
  0.354
  0.354
  0.354
  0.354
  0.354
  0.354
  0.354
  0.354
  0.354
  0.354
  0.354
  0.354
  0.354
  0.354
  0.354
  0.354
  0.354
  0.354
  0.354
  0.354
  0.354
  0.354
  0.354
  0.354
Average production assets, $m
  1,037
  1,072
  1,110
  1,152
  1,196
  1,243
  1,293
  1,347
  1,404
  1,465
  1,529
  1,597
  1,668
  1,744
  1,824
  1,909
  1,998
  2,092
  2,191
  2,295
  2,405
  2,521
  2,642
  2,770
  2,905
  3,046
  3,195
  3,352
  3,516
  3,689
  3,871
Working capital, $m
  730
  206
  213
  221
  230
  239
  249
  259
  270
  282
  294
  307
  321
  335
  351
  367
  384
  402
  421
  441
  462
  485
  508
  533
  558
  586
  614
  644
  676
  709
  744
Total debt, $m
  1,068
  1,126
  1,188
  1,256
  1,328
  1,406
  1,488
  1,576
  1,670
  1,769
  1,874
  1,986
  2,104
  2,228
  2,359
  2,498
  2,644
  2,798
  2,961
  3,132
  3,312
  3,502
  3,701
  3,911
  4,132
  4,364
  4,608
  4,865
  5,134
  5,418
  5,716
Total liabilities, $m
  1,701
  1,759
  1,821
  1,889
  1,961
  2,039
  2,121
  2,209
  2,303
  2,402
  2,507
  2,619
  2,737
  2,861
  2,992
  3,131
  3,277
  3,431
  3,594
  3,765
  3,945
  4,135
  4,334
  4,544
  4,765
  4,997
  5,241
  5,498
  5,767
  6,051
  6,349
Total equity, $m
  2,607
  2,149
  2,226
  2,308
  2,397
  2,492
  2,593
  2,700
  2,815
  2,936
  3,065
  3,201
  3,345
  3,497
  3,657
  3,827
  4,006
  4,194
  4,393
  4,602
  4,822
  5,053
  5,297
  5,554
  5,824
  6,107
  6,406
  6,719
  7,049
  7,396
  7,760
Total liabilities and equity, $m
  4,308
  3,908
  4,047
  4,197
  4,358
  4,531
  4,714
  4,909
  5,118
  5,338
  5,572
  5,820
  6,082
  6,358
  6,649
  6,958
  7,283
  7,625
  7,987
  8,367
  8,767
  9,188
  9,631
  10,098
  10,589
  11,104
  11,647
  12,217
  12,816
  13,447
  14,109
Debt-to-equity ratio
  0.410
  0.520
  0.530
  0.540
  0.550
  0.560
  0.570
  0.580
  0.590
  0.600
  0.610
  0.620
  0.630
  0.640
  0.650
  0.650
  0.660
  0.670
  0.670
  0.680
  0.690
  0.690
  0.700
  0.700
  0.710
  0.710
  0.720
  0.720
  0.730
  0.730
  0.740
Adjusted equity ratio
  0.550
  0.550
  0.550
  0.550
  0.550
  0.550
  0.550
  0.550
  0.550
  0.550
  0.550
  0.550
  0.550
  0.550
  0.550
  0.550
  0.550
  0.550
  0.550
  0.550
  0.550
  0.550
  0.550
  0.550
  0.550
  0.550
  0.550
  0.550
  0.550
  0.550
  0.550

CASH FLOW

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Net income, $m
  80
  120
  129
  138
  148
  159
  171
  183
  196
  210
  224
  381
  397
  414
  433
  452
  472
  494
  517
  540
  566
  592
  620
  649
  680
  712
  746
  782
  819
  859
  900
Depreciation, amort., depletion, $m
  213
  270
  273
  276
  279
  283
  286
  290
  294
  299
  303
  116
  121
  126
  132
  138
  145
  152
  159
  166
  174
  183
  191
  201
  211
  221
  232
  243
  255
  267
  280
Funds from operations, $m
  352
  390
  402
  414
  427
  442
  457
  473
  490
  509
  528
  496
  518
  541
  565
  590
  617
  646
  675
  707
  740
  775
  811
  850
  890
  933
  978
  1,025
  1,074
  1,126
  1,181
Change in working capital, $m
  10
  7
  7
  8
  8
  9
  10
  10
  11
  12
  12
  13
  14
  15
  15
  16
  17
  18
  19
  20
  21
  22
  23
  25
  26
  27
  29
  30
  32
  33
  35
Cash from operations, $m
  342
  383
  394
  406
  419
  433
  447
  463
  479
  497
  516
  483
  504
  526
  550
  574
  600
  627
  656
  687
  719
  752
  788
  825
  864
  906
  949
  995
  1,043
  1,093
  1,146
Maintenance CAPEX, $m
  0
  -75
  -78
  -80
  -83
  -87
  -90
  -94
  -98
  -102
  -106
  -111
  -116
  -121
  -126
  -132
  -138
  -145
  -152
  -159
  -166
  -174
  -183
  -191
  -201
  -211
  -221
  -232
  -243
  -255
  -267
New CAPEX, $m
  -94
  -36
  -38
  -41
  -44
  -47
  -50
  -54
  -57
  -61
  -64
  -68
  -72
  -76
  -80
  -85
  -89
  -94
  -99
  -104
  -110
  -116
  -122
  -128
  -135
  -142
  -149
  -156
  -164
  -173
  -182
Cash from investing activities, $m
  -179
  -111
  -116
  -121
  -127
  -134
  -140
  -148
  -155
  -163
  -170
  -179
  -188
  -197
  -206
  -217
  -227
  -239
  -251
  -263
  -276
  -290
  -305
  -319
  -336
  -353
  -370
  -388
  -407
  -428
  -449
Free cash flow, $m
  163
  273
  279
  285
  291
  299
  307
  315
  325
  335
  345
  305
  317
  329
  343
  357
  373
  389
  406
  424
  443
  463
  484
  506
  529
  554
  579
  607
  635
  665
  697
Issuance/(repayment) of debt, $m
  -8
  59
  63
  67
  72
  77
  83
  88
  94
  99
  105
  111
  118
  124
  131
  139
  146
  154
  162
  171
  180
  190
  199
  210
  221
  232
  244
  257
  270
  284
  298
Issuance/(repurchase) of shares, $m
  6
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Cash from financing (excl. dividends), $m  
  -11
  59
  63
  67
  72
  77
  83
  88
  94
  99
  105
  111
  118
  124
  131
  139
  146
  154
  162
  171
  180
  190
  199
  210
  221
  232
  244
  257
  270
  284
  298
Total cash flow (excl. dividends), $m
  149
  331
  341
  352
  364
  376
  389
  403
  418
  434
  450
  416
  434
  454
  474
  496
  519
  543
  568
  595
  623
  652
  683
  716
  750
  786
  824
  863
  905
  949
  995
Retained Cash Flow (-), $m
  -41
  -73
  -77
  -82
  -88
  -95
  -101
  -108
  -114
  -121
  -129
  -136
  -144
  -152
  -161
  -169
  -179
  -188
  -199
  -209
  -220
  -232
  -244
  -257
  -270
  -284
  -298
  -314
  -330
  -347
  -364
Prev. year cash balance distribution, $m
 
  531
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Cash flow adjustment, $m
 
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Cash available for distribution, $m
 
  789
  265
  270
  275
  282
  288
  296
  304
  313
  322
  280
  290
  302
  314
  327
  340
  354
  370
  386
  403
  420
  439
  459
  480
  502
  525
  550
  575
  602
  631
Discount rate, %
 
  4.30
  4.52
  4.74
  4.98
  5.23
  5.49
  5.76
  6.05
  6.35
  6.67
  7.00
  7.35
  7.72
  8.11
  8.51
  8.94
  9.39
  9.86
  10.35
  10.87
  11.41
  11.98
  12.58
  13.21
  13.87
  14.56
  15.29
  16.05
  16.86
  17.70
PV of cash for distribution, $m
 
  756
  242
  235
  227
  218
  209
  200
  190
  180
  169
  133
  124
  115
  105
  96
  86
  77
  68
  59
  51
  43
  36
  30
  24
  20
  15
  12
  9
  7
  5
Current shareholders' claim on cash, %
  100
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0

QIAGEN N.V. provides sample to insight solutions that transform biological materials into valuable molecular insights worldwide. It offers sample technologies to isolate, purify, and stabilize nucleic acids and proteins in plasmid deoxyribonucleic acid (DNA) purification, ribonucleic acid purification and stabilization, genomic and viral nucleic acid purification, DNA cleanup after polymerase chain reaction (PCR) and sequencing, and library preparation for sequencing applications; and assay technologies to detect molecular targets. The company provides the QIAGEN Knowledge Base, a repository of biological interactions and functional annotations; ingenuity variant analysis, a cloud-based platform to evaluate data generated by NGS technologies; QIAGEN Clinical Insight, an evidence-based clinical decision support solution; CLC Genomics Workbench for the analysis and visualization of data from NGS platforms; and GeneGlobe, a Web-based portal for researchers to search and select from pre-designed and custom PCR assay kits and NGS assay panels. It also offers instrumentation systems for laboratories to perform nucleic acid sample preparation, assay setup, target detection, and interpretation of genomic information. Its automation platforms include QIAsymphony, a modular system; Rotor-Gene Q, a rotary PCR cycler system; GeneReader NGS System; Modaplex, a multimodal automation system; EZ1 Advanced XL for automated nucleic acid purification; QIAcube, a sample processing instrument; QIAcube HT for automated nucleic acid purification; PyroMark, a detection platform; QIAgility, a benchtop instrument; QIAxcel for nucleic acid separation; and ESEQuant instruments that enable point of need testing in healthcare and other applications. The company has a collaboration with Singulex, Inc. to develop companion diagnostics. It serves molecular diagnostics, applied testing, pharma, and academia customers. QIAGEN N.V. was founded in 1986 and is headquartered in Venlo, the Netherlands.

FINANCIAL RATIOS  of  Qiagen (QGEN)

Valuation Ratios
P/E Ratio 89
Price to Sales 5.3
Price to Book 2.7
Price to Tangible Book
Price to Cash Flow 20.8
Price to Free Cash Flow 28.7
Growth Rates
Sales Growth Rate 4.4%
Sales - 3 Yr. Growth Rate %
EPS Growth Rate %
EPS - 3 Yr. Growth Rate %
Capital Spending Gr. Rate -19.7%
Cap. Spend. - 3 Yr. Gr. Rate -4.6%
Financial Strength
Quick Ratio 532
Current Ratio 0.1
LT Debt to Equity 40.9%
Total Debt to Equity 41%
Interest Coverage 4
Management Effectiveness
Return On Assets 2.5%
Ret/ On Assets - 3 Yr. Avg. 3.1%
Return On Total Capital 2.2%
Ret/ On T. Cap. - 3 Yr. Avg. 3%
Return On Equity 3.1%
Return On Equity - 3 Yr. Avg. 4.1%
Asset Turnover 0.3
Profitability Ratios
Gross Margin 63.2%
Gross Margin - 3 Yr. Avg. 64.7%
EBITDA Margin 21.5%
EBITDA Margin - 3 Yr. Avg. 24.8%
Operating Margin 7.4%
Oper. Margin - 3 Yr. Avg. 11.1%
Pre-Tax Margin 4.3%
Pre-Tax Margin - 3 Yr. Avg. 7.9%
Net Profit Margin 6%
Net Profit Margin - 3 Yr. Avg. 8.3%
Effective Tax Rate -40.4%
Eff/ Tax Rate - 3 Yr. Avg. -11.4%
Payout Ratio 0%

QGEN stock valuation input parameters

Revenue. Company's revenue (or sales) is always the starting point of any cash flow forecast. In the QGEN stock intrinsic value calculation we used $1338 million for the last fiscal year's total revenue generated by Qiagen. The default revenue input number comes from 2016 income statement of Qiagen. You may change it if you feel that it should be adjusted for some unusual circumstances that are not expected to be repeated in the future or if you already know (from interim financial statements, for example) that this year's revenue is going to be quite different.

Revenue growth rate. Forecasted future revenue growth rate is the most important input parameter for the intrinsic value calculation. Unlike other input parameters that are reasonably expected to be in line with their historic averages or their historic trends, the revenue growth rate by and large is a wild card: nobody really knows what the company's revenue will be in the future. Of course, the level of unpredictability is different for different industries (utility companies being the most predictable and, thus, less risky).
    We use three input parameters to forecast the revenue growth rate in our QGEN stock valuation model: a) initial revenue growth rate of 3.4% whose default value is the revenue growth rate in the most recent quarter compared to the quarterly revenue a year ago; b) terminal revenue growth rate of 5% whose default value is chosen to be close to the average nominal (i.e. not adjusted for inflation) GDP growth rate; and c) revenue decline factor of 0.9, which stipulates that revenue growth rate in each forecasted year will be equal to the difference of the revenue growth rate in the preceding year and the terminal revenue growth rate multiplied by this revenue decline factor (with the passage of time the revenue growth rate will be approaching the terminal revenue growth rate, but not quite reaching it - though the difference could be infinitesimally small).
    At the revenue decline factor of 1, the future revenue growth rate is forecasted to be constant and equal to the initial revenue growth rate. The smaller the revenue decline factor, the faster the revenue growth rate will approach the terminal revenue growth.

Discount rate. The discount rate is used for determining the present value of future cash flows: future cash flows are "discounted" as at normal conditions (that translate into positive expected return on investment) one dollar today is worth more than the same dollar in the future. Unlike all other valuation models, we use variable discount rate, i.e. it increases for each consecutive year. This is done to account for higher risk of cash flows coming in further in the future.
    The initial discount rate of 4.3%, whose default value for QGEN is calculated based on our internal credit rating of Qiagen, is applied to the cash flow expected to be received a year from now (well, actually, to be precise, in the financial year following the base year - the last year for which we have financial statements). For each consecutive year the discount rate is multiplied by the discount rate multiplier of 1.05, e.i. each year it increases by 5%. Feel free to change this number to correspond to your level of risk assessment of Qiagen.
    By the way, it is easy to set the discount rate to be constant (this would make comparison with other valuation models easier): just set the discount rate multiplier equal to 1 and chose the magnitude of the initial discount rate to your liking.

Variable cost ratio is the ratio of variable costs (i.e. costs that fluctuate with fluctuation of the volume of production) to the revenue expressed as a percentage. In the calculation of intrinsic value of QGEN stock the variable cost ratio is equal to 85.9%.

Fixed operating expenses is just that - expenses that are not dependant on the volume of production. They are set to $0 million in the base year in the intrinsic value calculation for QGEN stock. These expenses increase with the level of inflation in subsequent years.

Interest rate on debt is the average all-in rate of interest paid by the company on its debt. It is set at 3.5% for Qiagen.

Corporate tax rate of 27% is the nominal tax rate for Qiagen. In reality, companies find ways to pay much less taxes than that or not to pay them at all.

Cash flow adjustment could be used for any adjustment the investor deems necessary. Most commonly we use this field to account for stock options-related effects in excess of what is reported on the company's income statement. The cash flow adjustment is expressed as a percentage of the revenue, and in the current valuation of the QGEN stock is equal to 0%.

Production assets are the company's assets used for manufacturing products or provision of services. In the valuation model input table they are expressed as a percentage of revenue and for QGEN are equal to 77.5%.

Life of production assets of 13.8 years is the average useful life of capital assets used in Qiagen operations. It is used to calculate yearly capital expenditures needed to keep these assets in good order - we call it the maintenance CAPEX.

Working capital is the difference between the company's current assets and liabilities. In the model we use the ratio of working capital to revenue, which for QGEN is equal to 14.9%. A negative number means that the company is apt at using financial resources of its suppliers and customers; a large positive number, on the other hand, means that it either provides in-kind financing to others or is not good at managing its inventories.

Book value of equity - $2607 million for Qiagen - is used in calculation of the "floor" for intrinsic valuation based on the discounted cash flow (DCF) method. Even if the prospects are very bad for a company, its assets could always be sold now for their current fair market value.

Shares outstanding of 228.601 million for Qiagen is needed to calculate the intrinsic value of one share.

Market capitalization is used here only for reference purposes and as a quick check that the share price and the number of shares outstanding numbers are correct - something especially to be cognizant about at stock splits. So, the market capitalization of Qiagen at the current share price and the inputted number of shares is $7.2 billion.

RELATED COMPANIES Price Int.Val. Rating
TMO Thermo Fisher 174.01 75.59  str.sell
HOLX Hologic 37.63 16.08  str.sell
GNMK GenMark Diagno 9.54 0.21  str.sell
GHDX Genomic Health 29.74 3.18  str.sell
ILMN Illumina 190.68 71.07  str.sell
FMI Foundation Med 37.15 1.15  str.sell

COMPANY NEWS

▶ QIAGEN NV Value Analysis (NASDAQ:QGEN) : August 14, 2017   [Aug-14-17 06:08PM  Capital Cube]
▶ A Beat From Qiagen NV, but Only Half a Raise   [Jul-31-17 12:49PM  Motley Fool]
▶ Qiagen beats Street 2Q forecasts   [Jul-27-17 05:46PM  Associated Press]
▶ ETFs with exposure to QIAGEN NV : July 5, 2017   [Jul-05-17 01:07PM  Capital Cube]
▶ ETFs with exposure to QIAGEN NV : June 22, 2017   [Jun-22-17 04:18PM  Capital Cube]
▶ 3 Top Gene-Sequencing Stocks Poised for Solid Growth   [May-31-17 04:42PM  Motley Fool]
▶ QIAGEN NV's Getting It Done   [May-04-17 02:40PM  Motley Fool]
▶ Qiagen beats Street 1Q forecasts   [May-02-17 07:07PM  Associated Press]
▶ QIAGEN NV Value Analysis (NASDAQ:QGEN) : April 26, 2017   [Apr-26-17 04:30PM  Capital Cube]
▶ The Top Gene-Sequencing Stock to Buy in 2017   [Apr-20-17 04:20PM  Motley Fool]
▶ QIAGEN Posts 2016 Annual Report on its Website   [Apr-06-17 12:15PM  PR Newswire]
▶ QIAGEN NV Continues Its Turnaround   [04:16PM  at Motley Fool]
▶ Better Buy: Opko Health, Inc. vs. Qiagen   [Jan-19-17 10:58PM  at Motley Fool]
▶ Qiagen NV (QGEN) Hedge Funds Are Snapping Up   [Dec-07-16 08:26AM  at Insider Monkey]
▶ Qiagen NV Jumps After Beating Its Earnings Guidance   [Nov-03-16 04:12PM  at Motley Fool]
▶ QIAGEN Launches QIAscout for Single-cell Isolation   [Oct-20-16 04:05PM  PR Newswire]
Stock chart of QGEN Financial statements of QGEN
Valuation of Stocks

The paper VALUATION OF STOCKS: The Quest for Intrinsic Value provides a detailed description of our valuation model and discloses the calculation algorithm.

FREE DOWNLOAD
Follow us on:   twitter   twitter   twitter   twitter

VALUATION THEORY       ASSET ALLOCATION

About X-FIN       Site news       Privacy policy       Terms of use       FAQ

Copyright © X-FIN.com 2005-2017. All rigths reserved.